Market Cap 282.43M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.73
Volume 233,003
Avg Vol 1,137,628
Day's Range N/A - N/A
Shares Out 68.06M
Stochastic %K 12%
Beta 2.37
Analysts Sell
Price Target $22.50

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
betonthenews
betonthenews Sep. 16 at 3:33 PM
$OMER From 10-Q2 filed on Aug 14: As of June 30, 2025, we had cash, cash equivalents, and short-term investments of $28.7 million. On July 28, 2025, we issued and sold 5,365,853 shares of our common stock at a price of $4.10 per share, We received approximately $20.6 million in cash proceeds net of offering expenses. from the sale of our common stock through the ATM facility and have received $2.1 million subsequent to June 30, 2025. 28.7+20.6+2.1=$51.4M cash for Q3, assuming $8M/month cost, Q3 expenses are $24M, 51.4-24=$27.4M, OMER has $27.4M on hand as of Sept 30, OMER is in position of June and July again, the change starts with first domino chip to fall of label talk (imply approval) on schedule or not in OCT, IMO.
0 · Reply
MinnieSteve3
MinnieSteve3 Sep. 16 at 3:16 PM
$OMER No news, no volume, no movement. So we wait.
0 · Reply
robertward
robertward Sep. 16 at 12:22 PM
$OMER can someone remind me what the wording was when Dr. D was talking about the potential partnership in the near future… I would’ve thought we’d have heard something by now. Maybe ironing out all the details takes way more time than I assume or else the partnership hinges on TMA approval, which I didn’t think was the case.
2 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 12:05 PM
$OMER Current Stock Price: $4.09 Contracts to trade: $5 OMER Sep 19 2025 Call Entry: $0.14 Exit: $0.23 ROI: 72% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DimondTrade100
DimondTrade100 Sep. 16 at 8:12 AM
$OMER Beneficiary of technology adoption; cadence of contracts will dictate performance
0 · Reply
robertward
robertward Sep. 15 at 11:55 PM
$OMER when r we getting some good news 🗞️??????? So tired of waiting 😫😡🥵🤬 Maybe tomorrow 🤔🤷🏼‍♂️
0 · Reply
MinnieSteve3
MinnieSteve3 Sep. 15 at 3:33 PM
$OMER Almost 1,100 Sep 19 $5 call option contracts have been traded in the first 2 hours today. Can't tell at this time though if the trades were opening or closing a position or what combination thereof. Have to wait until tomorrow to see the change in the open interest.
2 · Reply
capntrps
capntrps Sep. 15 at 2:24 PM
$OMER kinda surprised how boring this has gotten. Kinda expected a few rips along the way vs a slow sell off. Who knows, maybe atm. Getting closer to a big move one way or the other.... Seems completely binary to me at this point, unless some magical licencing deal presents itself on another part of the pipeline.
3 · Reply
LeaLeb
LeaLeb Sep. 15 at 2:14 PM
$OMER Current price action saying that market is very skeptical in OMER's ability to get financing or Narso through the finish line. One of the 2 happens and this thing will rip faces.
0 · Reply
LeaLeb
LeaLeb Sep. 15 at 2:12 PM
$OMER Only one thing in my portfolio down the last month.. not gonna say names.
0 · Reply
Latest News on OMER
Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 4:41 PM EDT - 27 days ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript


Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 4 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results


Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 5 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight


Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 6 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript


Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:22 PM EST - 10 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript


Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:02 PM EST - 10 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results


Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:05 AM EDT - 1 year ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript


Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript


Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript


betonthenews
betonthenews Sep. 16 at 3:33 PM
$OMER From 10-Q2 filed on Aug 14: As of June 30, 2025, we had cash, cash equivalents, and short-term investments of $28.7 million. On July 28, 2025, we issued and sold 5,365,853 shares of our common stock at a price of $4.10 per share, We received approximately $20.6 million in cash proceeds net of offering expenses. from the sale of our common stock through the ATM facility and have received $2.1 million subsequent to June 30, 2025. 28.7+20.6+2.1=$51.4M cash for Q3, assuming $8M/month cost, Q3 expenses are $24M, 51.4-24=$27.4M, OMER has $27.4M on hand as of Sept 30, OMER is in position of June and July again, the change starts with first domino chip to fall of label talk (imply approval) on schedule or not in OCT, IMO.
0 · Reply
MinnieSteve3
MinnieSteve3 Sep. 16 at 3:16 PM
$OMER No news, no volume, no movement. So we wait.
0 · Reply
robertward
robertward Sep. 16 at 12:22 PM
$OMER can someone remind me what the wording was when Dr. D was talking about the potential partnership in the near future… I would’ve thought we’d have heard something by now. Maybe ironing out all the details takes way more time than I assume or else the partnership hinges on TMA approval, which I didn’t think was the case.
2 · Reply
BillionerOfKing
BillionerOfKing Sep. 16 at 12:05 PM
$OMER Current Stock Price: $4.09 Contracts to trade: $5 OMER Sep 19 2025 Call Entry: $0.14 Exit: $0.23 ROI: 72% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DimondTrade100
DimondTrade100 Sep. 16 at 8:12 AM
$OMER Beneficiary of technology adoption; cadence of contracts will dictate performance
0 · Reply
robertward
robertward Sep. 15 at 11:55 PM
$OMER when r we getting some good news 🗞️??????? So tired of waiting 😫😡🥵🤬 Maybe tomorrow 🤔🤷🏼‍♂️
0 · Reply
MinnieSteve3
MinnieSteve3 Sep. 15 at 3:33 PM
$OMER Almost 1,100 Sep 19 $5 call option contracts have been traded in the first 2 hours today. Can't tell at this time though if the trades were opening or closing a position or what combination thereof. Have to wait until tomorrow to see the change in the open interest.
2 · Reply
capntrps
capntrps Sep. 15 at 2:24 PM
$OMER kinda surprised how boring this has gotten. Kinda expected a few rips along the way vs a slow sell off. Who knows, maybe atm. Getting closer to a big move one way or the other.... Seems completely binary to me at this point, unless some magical licencing deal presents itself on another part of the pipeline.
3 · Reply
LeaLeb
LeaLeb Sep. 15 at 2:14 PM
$OMER Current price action saying that market is very skeptical in OMER's ability to get financing or Narso through the finish line. One of the 2 happens and this thing will rip faces.
0 · Reply
LeaLeb
LeaLeb Sep. 15 at 2:12 PM
$OMER Only one thing in my portfolio down the last month.. not gonna say names.
0 · Reply
rongside
rongside Sep. 15 at 11:10 AM
$OMER This is from an abstract concerning CAR-T therapy: "Various markers of endothelial injury have been investigated in CAR-T cell recipients, including markers of complement activation, such as soluble C5b-9, endothelial dysfunction (angiopoietin-2, VCAM1, ICAM-1), inflammation, and thrombosis (von Willebrand antigen, ADAMTS13, thrombomodulin). The expression level of these endothelial injury markers has been identified as impaired in CAR-T cell recipients, not only when compared with healthy controls but also among patients with severe CRS/ICANS and those with mild toxicities or without toxicities" TA-TMA is not the only indication that Narsoplimab addresses. It may also be applicable to adverse events resulting during CAR-T therapy. When you include indications such as AHUS and ARDS the potential of Narso is truly impressive. GD doesn't want to give this away as it is a potential cash cow. This will only be partnered in the European and EX - USA market.
1 · Reply
Niuniucat
Niuniucat Sep. 14 at 4:26 PM
$OMER Anyone read the following article? Is it legit or completely bullshit? I haven’t due to no access
5 · Reply
Phase3
Phase3 Sep. 14 at 2:08 PM
$OMER How many chickens?
1 · Reply
Iceman89
Iceman89 Sep. 14 at 3:47 AM
$OMER Since bullish PGEN approval comments have been posted here, then I think REPL CRL is relevant for analysis here too, atleast a little bit. It seems that it is important for OMER to show and prove the homogenity of their patient population to the relevant placebo group(s). The next research paper should help clarify a lot. 1st line and 2nd line (refractory?) should be enough for Narsoplimab? Are 28 patients enough for this distinction? In REPL, it was purely 2nd line and scattered 1st line treatments and disease burden + combination therapy.
1 · Reply
robertward
robertward Sep. 14 at 12:14 AM
$OMER AI answer: Combined Effect: If a $2 billion partnership were to happen in conjunction with or after TMA approval, the combined effect would likely be multiplicative. The partnership would provide immediate financial stability, while the approval would establish a long-term revenue stream, dramatically changing the company's valuation. This scenario would most likely push the stock price to the high end of the forecast range ($36 to $47) and potentially beyond.
0 · Reply
guinnessnu
guinnessnu Sep. 13 at 9:36 PM
$OMER asked ChatGPT about odds of FDA approving narsoplimab: all together, I’d estimate the odds of FDA approval of narsoplimab for TA-TMA by the target date (December 2025) are somewhere between 70% and 85%. If I had to pick a single number, I might say ~80% chance, with maybe a 20% chance of rejection or further delay.
3 · Reply
GreenCross
GreenCross Sep. 13 at 4:14 PM
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 9:22 AM
Enter: $OMER OCT 17 2025 $5 CALLS Buy in Price: $0.65 - $0.65 Take Profit: $0.87 Stop Bleeding: $0.57 ROI Potential: 34% Exit Within: 67 Minutes https://moneygroup.us/alerts
0 · Reply
huskygold
huskygold Sep. 13 at 6:48 AM
$OMER for fun and understanding ChatGPT may be hallucinating, here is part of its answer to my question on what might be Omeros’ share price in early 2026 assuming Narso approval and partnership—both under current stock market conditions and a downturn over next six months. Thoughts? Go Omeros! “A) Approval + partner, no broad market shock • Equity value rough range: $0.9B–$2.0B • Per-share rough range: $14$32 • Rationale: approval + partner de-risks cash and commercialization; orphan-drug comps can carry mid single-digit EV/S on year-2 revenue when sentiment is constructive. B) Same (approval + partner), but a U.S. market downturn in next 6 months • Expect multiple compression and slower uptake (budget caution, access friction). • Equity value rough range: $0.4B–$1.1B • Per-share rough range: $6$18 • Rationale: even with approval, risk-off tape often takes EV/S down to ~2–4× and penalizes micro-caps; launch curves can lag in recessions/bear tapes.”
2 · Reply
naturegirl669
naturegirl669 Sep. 13 at 2:38 AM
$OMER - "CDC estimates indicate 1,231,440 Americans died from COVID-19." https://www.yahoo.com/news/articles/opinion-rfk-jr-deadly-covid-140000647.html
1 · Reply
UltimoDaBaggie
UltimoDaBaggie Sep. 13 at 1:01 AM
$OMER @ipdamages I read your msg stating narso failed aHUS, IgAN, and COVID. I have to disagree about COVID. iSPY study was an exploratory one and there was a numerical improvement. Most likely, narso is effective in a subset of COVID patients. The issue was a predictor (serum marker) was not available. From OMER’s subsequent public disclosures, it seemed like they were finally able to identify one in UK. Further testing was underway but then finances got messed up. IMO, OMER’s biggest asset is that predictor. Cuz narso is likely effective in other etiologies of DIC. If we had a reliable predictor, narso could be used on those patients and save lots of lives. OTH, such a clinical trial would be very difficult to undertake even if there was a reliable predictor
2 · Reply
WinstonWolfff
WinstonWolfff Sep. 12 at 6:41 PM
$OMER Just topping off my tank with a few final buys. So many high risk moves by people inside and outside of the company that I believe there is a huge safety net for them. Their safety, is our safety. We are always the last to know……
1 · Reply